T-20 for HIV - horizon scanning review

Record ID 32002000547
Authors' objectives:

To summarise the current research evidence on T-20 for HIV.

Authors' recommendations: - Clinical impact: T-20 is a novel product to slow the progression of HIV infection. If early clinical trial results are confirmed, T-20 may have a significant clinical impact at least in the short term. - Service impact: Although it is difficult to estimate at this time, there is unlikely to be a significant service impact associated with the introduction of T-20 for HIV. - Additional factors: Due to the nature of HIV and the size of the patient group failing therapy at all levels, there may be a significant patient interest in the introduction of T-20 for HIV. - Financial and overall NHS impact: Due to the lack of cost data it is difficult to estimate the likely financial impact at this time. However, due to the potential size of the patient group the introduction of T-20 for HIV may have a significant financial impact.
Authors' methods: Overview
Project Status: Completed
Year Published: 2002
URL for published report: http://www.hsric.nihr.ac.uk/search
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • HIV Envelope Protein gp120
  • HIV Infections
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name: c.packer@bham.ac.uk
Contact Email: c.packer@bham.ac.uk
Copyright: National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.